Imatinib Actavis Group 100mg Film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

imatinib actavis group 100mg film-coated tablets

actavis group ptc ehf - imatinib mesilate - film-coated tablet - 100 milligram(s) - other antineoplastic agents - antineoplastic agents, protein kinase inhibitor - imatinib actavis group is indicated for the treatment of - paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult patients with ph+ cml in blast crisis. - adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement.

Topotecan Actavis European Union - English - EMA (European Medicines Agency)

topotecan actavis

actavis group ptc ehf - topotecan - uterine cervical neoplasms; small cell lung carcinoma - antineoplastic agents, - topotecan monotherapy is indicated for the treatment of patients with relapsed small cell lung cancer [sclc] for whom re-treatment with the first-line regimen is not considered appropriate. topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage ivb disease. patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.,

Imatinib Actavis Group 400mg Film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

imatinib actavis group 400mg film-coated tablets

actavis group ptc ehf - imatinib mesylate - film-coated tablet - 400 milligram(s) - other antineoplastic agents - antineoplastic agents, protein kinase inhibitor - imatinib actavis group is indicated for the treatment of - paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult patients with ph+ cml in blast crisis. - adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement.

VORICONAZOLE ACTAVIS 200 Milligram Film Coated Tablet Ireland - English - HPRA (Health Products Regulatory Authority)

voriconazole actavis 200 milligram film coated tablet

actavis group ptc ehf - voriconazole - film coated tablet - 200 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - it is indicated in adults and children aged 2 years and above as follows: - treatment of invasive aspergillosis. - treatment of candidemia in non-neutropenic patients. - treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). - treatment of serious fungal infections caused by scedosporium spp. and fusarium spp

VORICONAZOLE ACTAVIS 50 Milligram Film Coated Tablet Ireland - English - HPRA (Health Products Regulatory Authority)

voriconazole actavis 50 milligram film coated tablet

actavis group ptc ehf - voriconazole - film coated tablet - 50 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - it is indicated in adults and children aged 2 years and above as follows: - treatment of invasive aspergillosis. - treatment of candidemia in non-neutropenic patients. - treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). - treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.

Desloratadine Actavis European Union - English - EMA (European Medicines Agency)

desloratadine actavis

actavis group ptc ehf - desloratadine - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistamines for systemic use, - treatment of allergic rhinitis and urticaria.

BISOPROLOL FUMARATE ACTAVIS 10 Milligram Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

bisoprolol fumarate actavis 10 milligram tablets

actavis group ptc ehf - bisoprolol fumarate - tablets - 10 milligram - beta blocking agents, selective

BISOPROLOL FUMARATE ACTAVIS 5 Milligram Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

bisoprolol fumarate actavis 5 milligram tablets

actavis group ptc ehf - bisoprolol fumarate - tablets - 5 milligram - beta blocking agents, selective

Valsartan Actavis 40 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

valsartan actavis 40 mg film-coated tablets

actavis group ptc ehf - valsartan - film-coated tablet - 40 milligram(s) - angiotensin ii antagonists, plain; valsartan

Docetaxel Actavis 20mg/0.5ml concentrate and solvent for solution for infusion Malta - English - Medicines Authority

docetaxel actavis 20mg/0.5ml concentrate and solvent for solution for infusion

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - docetaxel - concentrate and solvent for solution for infusion - docetaxel 40 milligram(s)/millilitre - antineoplastic agents